Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study

Summary: Preclinical studies suggest synergistic effects between androgen receptor inhibitors and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. This phase 2 trial (NCT05223582) evaluates neoadjuvant fuzuloparib plus abiraterone in 35 treatment-naive men with localized high-risk pr...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tingwei Zhang, Beihe Wang, Yu Wei, Hualei Gan, Bangwei Fang, Xiaomeng Li, Junlong Wu, Xiaojie Bian, Jianfei Wang, Stephen J. Freedland, Shenglin Huang, Dingwei Ye, Yao Zhu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-03-01
Edice:	Cell Reports Medicine
Témata:	Prostate cancer neoadjuvant fuzuloparib abiraterone
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666379125000916
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!